Amphion Innovations plc Directors Dealings
Board Members Receive Shares in Lieu of Fees
London and New York, 16 September 2008 – mphion Innovations plc (LSE: AMP), the developer of medical and technology businesses, announces today that Board Members Richard Mansell-Jones, R. James Macaleer, and Anthony Henfrey have, in lieu of their directors’ fee for the periods 1 April to 30 June and 1 July to 30 September, received their full remuneration in the form of ordinary shares priced at 21.5p at 30 June and 19.75 at 4 September, the closing mid market prices.
Richard Mansell-Jones, Chairman of Amphion, received 90,982 ordinary shares, bringing his total holdings of the Company to 2,693,774, representing 2.066% of the Company’s issued ordinary share capital. Pursuant to Rule 13 of the AIM Rules this constitutes a related party transaction and the independent Directors consider, having consulted with its Nominated Adviser, that the terms of the transaction are fair and reasonable insofar as its shareholders are concerned.
R. James Macaleer received 45,491 ordinary shares, bringing his total beneficiary holding of the Company to 19,917,054, representing 15.276% of the Company’s issued ordinary share capital.
Anthony Henfrey received 45,491 ordinary shares, bringing his total holding of the Company to 904,352 representing 0.694% of the Company’s issued ordinary share capital.
Admission of the 181,964 new ordinary shares, ranking pari passu, is expected 19 September 2008.
For further information please contact
Amphion Innovations
Charlie Morgan
+1 212 210 6224
Cardew Group
Tim Robertson/ Jamie Milton/Matthew Law
+44 20 7930 0777
Charles Stanley (Nominated Adviser)
Mark Taylor/ Freddy Crossley
+44 20 7149 6000
About Amphion Innovations plc
Amphion (LSE: AMP) builds shareholder value in high growth companies in the medical and technology sectors, by using a focused, hands-on company building approach, based on decades of experience in both the US and UK. Amphion has significant shareholding in 10 Partner Companies, developing proven technologies targeting substantial commercial marketplaces, each in excess of $1 billion. Each Partner Company is chosen with the goal of achieving an exit valuation in excess of $100 million.
On the web: www.amphionplc.com
